ICAAC 48th Washington 2008

48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington DC

Antiretroviral Pregnancy Registry finds no increase in congenital anomalies with exposure to tenofovir

No association between maternal antiretrovirals in pregnancy and congenital anomalies

Pharmacokinetics of saquinavir/ritonavir in pregnancy

Course of labour in pregnant HIV-positive women with no contraindication for vaginal delivery

Four weeks of antiretroviral prophylaxis is sufficient for HIV-exposed infants

HAART suppresses genital tract HIV shedding in HIV/HSV co-infected women

Efavirenz significantly reduces levels of some oral contraceptives

Lack of efficacy of isoniazid (INH) prophylaxis and PK evaluation in South African infants

48-week data for darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents

Greater lipodystrophy risk in older US children with low viral load

Studies of pipeline drugs: RDEA806, PRO140, bevirimat, elvucitabine

Other antiretroviral studies at ICAAC

High rate of rash in HIV negative volunteers combining raltegravir and darunavir

Bone loss in SMART study

Parathyroid hormone and vitamin D levels in patients using tenofovir

Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

Statin use in HIV-positive patients

HIV reinfection reported in 10% of couples in Zambian study

Drug interaction studies with approved drugs

Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients